Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QYKCV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TWEAKR ADC 3d
|
|||||
| Synonyms |
TWEAKR-ADC-3d
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Bladder cancer [ICD11:2C94]
Investigative
Colon cancer [ICD11:2B90]
Investigative
Lung mucoepidermoid carcinoma [ICD11:2C25]
Investigative
Pancreatic ductal adenocarcinoma [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.2
|
|||||
| Antibody Name |
BAY-356
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)
|
Antigen Info | ||||
| Payload Name |
Kinesin spindle protein (KSP) inhibitor 3d
|
Payload Info | ||||
| Therapeutic Target |
Kinesin-like protein KIF11 (KIF11)
|
Target Info | ||||
| Linker Name |
Open-chain glycine maleimide
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 600 nM | Positive TNFRSF12A expression (TNFRSF12A +++/++) | ||
| Method Description |
Cytotoxicity of ADCs, SMOL KSP inhibitors, and payload metabolite were determined in TWEAKR-positive cancer cell lines 72 h after treatment with the Promega CellTiter Glo (CTG) cell viability assay according to manufacturers instructions.
|
||||
| In Vitro Model | Lung mucoepidermoid carcinoma | NCI-H292 cells | CVCL_0455 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 600 nM | Positive TNFRSF12A expression (TNFRSF12A +++/++) | ||
| Method Description |
Cytotoxicity of ADCs, SMOL KSP inhibitors, and payload metabolite were determined in TWEAKR-positive cancer cell lines 72 h after treatment with the Promega CellTiter Glo (CTG) cell viability assay according to manufacturers instructions.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 600 nM | Positive TNFRSF12A expression (TNFRSF12A +++/++) | ||
| Method Description |
Cytotoxicity of ADCs, SMOL KSP inhibitors, and payload metabolite were determined in TWEAKR-positive cancer cell lines 72 h after treatment with the Promega CellTiter Glo (CTG) cell viability assay according to manufacturers instructions.
|
||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.